NEWSROOM | Galderma

Acne Awareness Month: let’s talk about acne

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years

Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations

International Congress of Dermatology 2025: Galderma’s Scientific Presentations

Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering

Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba

Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance

Galderma shareholders approve all Annual General Meeting proposals

Galderma launches "Scratch Resistance" campaign to validate the physical and emotional burdens of atopic dermatitis

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®

Galderma launches Sculptra® in China, further fueling its growth into one of the fastest growing aesthetics markets